Drug intelligence / Profile preview

WTX201

Development stage: Preclinical
Lead developer: Wntrix
Modality: Small Molecules

Overview

WTX201 is a small molecule inhibitor of the Wnt signaling pathway currently under development by Wntrix. It is being investigated for the treatment of gastrointestinal cancers, specifically liver cancer (hepatocellular carcinoma) and pancreatic cancer. The Wnt pathway is frequently dysregulated in these malignancies, contributing to tumor growth, metastasis, and resistance to therapy. WTX201 is currently in the IND-enabling stage of development, aimed at progressing toward clinical trials for patients with Wnt-driven solid tumors.

Other names: WTX201WTX-201WTX 201

Beyond the preview

Go deeper on WTX201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTX201.

Explore the full profile